page contents

Home / All About Herbs / About Acai Monograph

acai berries

© RicAguiar

An acai monograph for the home

Latin Name: Euterpe oleracea, Euterpe badiocarpa

Common Names: acai, açaí (pronounced AH-sigh-EE)


This acai monograph provides basic information about acai herbal medicine: common names, usefulness and safety, and resources for more information.


Acai Basics

The acai palm tree, native to tropical Central and South America, produces a deep purple fruit. The word “acai,” which comes from a language of the native people of the region, means “fruit that cries.” The acai fruit has long been an important food source for indigenous peoples of the Amazon region.

Acai products have become popular in the United States, where they have been marketed for weight-loss and anti-aging purposes.

The Federal Trade Commission has taken action against companies that marketed acai weight loss products in allegedly deceptive ways.

Acai fruit pulp has been used experimentally as an oral contrast agent for magnetic resonance imaging (MRI). Acai products are available as juices, powders, tablets, and capsules.

Acai in Research

Very little research has been done in people on the health effects of acai products.

Acai Research Results

There’s no definitive scientific evidence based on studies in people to support the use of acai for any health-related purpose. No independent studies have been published in peer-reviewed journals that substantiate claims that acai alone promotes rapid weight loss. Researchers who investigated the safety profile of an acai-fortified juice in rats observed that there were no body weight changes in animals given the juice compared with animals that didn’t receive it.

A preliminary study suggested that eating acai fruit pulp might reduce blood sugar and cholesterol levels in overweight people. Laboratory studies have focused on acai’s potential antioxidant properties, and a juice blend with acai as the main ingredient has been shown to have an antioxidant effect in people. (Antioxidants are substances that may protect cells against certain types of damage.)

Acai Safety

There is little reliable information about the safety of acai as a supplement. It is widely consumed as an edible fruit or as a juice. Consuming acai might affect MRI test results. If you use acai products and are scheduled for an MRI, check with your health care provider.

Acai References

Acai. Natural Medicines Web site. Accessed at on March 26, 2015. [Database subscription].

Federal Trade Commission. FTC Permanently Stops Fake News Website Operator that Allegedly Deceived Consumers about Acai Berry Weight-Loss Products. Federal Trade Commission Web site. Accessed at on March 27, 2015.

Jensen GS, Wu X, Patterson KM, et al. In vitro and in vivo antioxidant and anti-inflammatory capacities of an antioxidant-rich fruit and berry juice blend. Results of a pilot and randomized, double-blinded, placebo-controlled, crossover study. Journal of Agricultural and Food Chemistry. 2008;56(18):8326-8333.

Marcason W. What is the açaí berry and are there health benefits? Journal of the American Dietetic Association. 2009;109(11):1968.

Schauss AG, Clewell A, Balogh L, et al. Safety evaluation of an acai-fortified fruit and berry functional juice beverage (MonaVie Active®). Toxicology. 2010;278(1):46-54.

Schreckinger ME, Lotton J, Lila MA, et al. Berries from South America: a comprehensive review on chemistry, health potential, and commercialization. Journal of Medicinal Food. 2010;13(2):233-246.

Udani JK, Singh BB, Singh VJ, et al. Effects of acai (Euterpe oleracea Mart.) Berry preparation on metabolic parameters in a healthy overweight population: a pilot study. Nutrition Journal. 2011;10:45.


PubMed Articles About

Source: National Center for Biotechnology Information (NCBI)[Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [1988] – [cited 2018 Apr 5]. Available from:

Wang, CX., Wu, D., Yang, PP., Wu, QH., (2020) [Efficacy and safety of non-vitamin K antagonist versus vitamin K antagonist oral anticoagulants in the prevention and treatment of thrombotic disease in active cancer patients: a systematic review and meta-analysis of randomized controlled trials].

We aimed to compare the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonist (VKA) in the prevention and treatment of thrombotic diseases in patients with active cancer. To find randomized controlled trials (RCT) in which NOACs were compared VKAs in active cancer, we searched the electronic databases (PubMed, Web of Science and Clinical Trials) up to May 2019 and and languages restricted to Chinese and English. According to the screening strategy, two researchers independently screened and extracted literature, evaluated the quality of literature, the suitability of collected cross study data for analysis, and tested the heterogeneity. The relative risk () and 95% confidence interval (95%) of major bleeding, clinically related non-major bleeding, VTE, stroke and all-cause mortality in active cancer patients with VTE, active cancer patients with non-valvular atrial fibrillation (NVAF) was calculated and the results were compared between NOAC with VKA. A total of 9 RCTs were included, including 5 cancers with VTE (5/9) and 4 cancers with NVAF (4/9). A total of 5 867 patients were included. After excluding 1 818 (30.99%) patients with cancer history, 4 049 (68.86%) patients with active cancer were statistically analyzed. Among them, 2 278 (56.26%) received NOAC treatment, 1 771 patients (43.74%) received VKA treatment. The quality of the included documents was high (all scores were>5 points), and the data of each included document could be summarized and analyzed (>0.05). The heterogeneity of main outcome events was very low ( = 0). In VTE patients with active cancer, NOACs were more effective in reducing recurrence of VTE (=0.55, 95% 0.36 -0.84; 0.005) and clinically related non-major bleeding (=0.77, 95% 0.60 -0.98; 0.03) than VKAs. In NVAF patients with active cancer, efficacy of NOACs and VKAs was similar in terms of reducing VTE, stroke, clinically related non-major bleeding, major bleeding and all-cause mortality events (>0.05). For patients with active cancer accompanied by VTE, NOAC may has more advantages in efficacy and safety compared to VKA in the prevention and treatment of thrombotic diseases.

Zhang, ZD., Liu, H., Lyu, J., Yu, DD., Sun, MH., (2020) [Systematic review and Meta-analysis of efficacy and safety of Xiangsha Yangwei Pills in treatment of chronic gastritis].

To systematically evaluate the efficacy and safety of Xiangsha Yangwei Pills in the treatment of chronic gastritis. Compu-ter retrieval was performed for Cochrane Library, Medline, EMbase, China Knowledge Network Database(CNKI), China Biomedical Literature Service System(SinoMed), Chongqing Weipu Chinese Science and Technology Journal Database(VIP) and WanFang Database(WanFang) randomized controlled trials about Xiangsha Yangwei Pills combined with Western medicine in the treatment of chro-nic gastritis. The retrieval time ranged from the establishment of the library to April 26, 2019. Meta-analysis was performed by RevMan 5.3 software after two independent researchers conducted literature screening, data extraction and quality evaluation according to inclusion and exclusion criteria. A total of 1 720 patients were enrolled in 18 RCT. According to the classification of chronic gastritis, they were divided into three subgroups: chronic gastritis, chronic atrophic gastritis and chronic superficial gastritis. The results of Meta-ana-lysis showed that the efficacy of Xiangsha Yangwei Pills combined with Western medicine in treating chronic gastritis was higher than that of Western medicine. As for the recurrence rate, Xiangsha Yangwei Pills combined with Western medicine was lower than Western medicine. And there was no statistical difference about helicobacter pylori(Hp) eradication rate between Xiangsha Yangwei Pills combined with Western medicine as well as Western medicine. In terms of the incidence of adverse reactions, Xiangsha Yangwei Pills combined with Western medicine was lower than Western medicine, and no serious adverse reaction was reported. The results of this systematic review showed that compared with the conventional Western medicine group, Xiangsha Yangwei Pills combined with Western medicine can significantly alleviate clinical symptoms of chronic gastritis, with fewer adverse reactions. However, due to the low methodological quality of the included studies and the reliability of the impact conclusions, high-quality multi-center, large-sample, randomized, double-blind controlled trials are needed for validation.

Clifford, T., Jeffries, O., Stevenson, EJ., Davies, KAB., (2020) The effects of vitamin C and E on exercise-induced physiological adaptations: a systematic review and Meta-analysis of randomized controlled trials.

We conducted a systematic review and meta-analysis of randomized controlled trials examining the effect of vitamin C and/or E on exercise-induced training adaptations. Medline, Embase and SPORTDiscus databases were searched for articles from inception until June 2019. Inclusion criteria was studies in adult humans where vitamin C and/or E had to be consumed alongside a supervised exercise training program of ≥4 weeks. Nine trials were included in the analysis of aerobic exercise adaptations and nine for resistance training (RT) adaptations. Vitamin C and/or E did not attenuate aerobic exercise induced improvements in maximal aerobic capacity (O (SMD -0.14, 95% CI: -0.43 to 0.15,  = 0.35) or endurance performance (SMD -0.01, 95% CI: -0.38 to 0.36,  = 0.97). There were also no effects of these supplements on lean mass and muscle strength following RT (SMD -0.07, 95% CI: -0.36 to 0.23,  = 0.67) and (SMD -0.15, 95% CI: -0.16 to 0.46,  = 0.35), respectively. There was also no influence of age on any of these outcomes ( > 0.05). These findings suggest that vitamin C and/or E does not inhibit exercise-induced changes in physiological function. Studies with larger sample sizes and adequate power are still required.

Chen, G., Chen, Y., Chen, Z., Gao, S., Zhang, P., Zhang, H., Huang, Y., Lin, Y., Wei, L., (2021) Sanao decoction for asthma: Protocol of a systematic review.

Asthma is a chronic inflammatory disease characterized by recurrent attacks of breathlessness and wheezing, which often worsen at night or in the early morning and vary from person to person in severity and frequency. Sanao decoction (SAD), as a traditional Chinese medicine compound, has a long history of clinical application in the treatment of respiratory diseases. Whereas neither systematic nor meta-analysis of randomized controlled articles explain the efficacy of SAD in treating asthma. Therefore, we provide a protocol to evaluate the efficacy and safety of SAD for asthma.